Tribunal issues detailed directions on interest adjustment, income exclusion, transfer pricing, expenses reimbursement, and deductions

The tribunal provided detailed directions on various issues, including adjustment of interest on advances, exclusion of income from patent infringement settlement, rejection of entity-level margins for transfer pricing, examination of reimbursement of expenses, deduction of disallowed expenditure in a sister concern, and allowance of deductions for ESOP expenses and R&D expenditures. The tribunal emphasized adherence to segmental financials, rational allocation of overheads, and compliance with legal precedents. The appeal was partly allowed for statistical purposes.

---

---

Issues Involved:
1. Adjustment of interest on advances to Associated Enterprises (AEs).
2. Exclusion of income from settlement of patent infringement from operating profits.
3. Rejection of segmental results and adoption of entity-level operating margins for Transfer Pricing adjustments.
4. Inclusion of reimbursement of expenses in operating sales.
5. Deduction of disallowed expenditure in a sister concern.
6. Benefit of the +/- 5% standard deduction under section 92C(2).
7. Deduction under section 10B for the Export Oriented Undertaking.
8. Deduction of Employee Stock Option Scheme (ESOP) expenses.
9. Apportionment of common corporate overhead expenses.
10. Depreciation on non-compete fee.
11. Weighted deduction under section 35(2AB).
12. Deduction for R&D expenditure not eligible for weighted deduction.

Detailed Analysis:

1. Adjustment of Interest on Advances to AEs:
The issue was whether the DRP's direction to adopt an interest rate of LIBOR + 2% instead of LIBOR + 1% was correct. The tribunal held that since the assessee charged LIBOR + 1% and the DRP accepted +1% for guarantee fee, there was no reason to vary the interest rate. It was concluded that LIBOR + 1% is at arm's length for trade advances. This decision was specific to the facts of this case and should not be considered a precedent.

2. Exclusion of Income from Settlement of Patent Infringement from Operating Profits:
The assessee included Rs. 26.91 crores from a patent infringement settlement in its operating profits. The tribunal upheld the DRP's decision to exclude this amount, stating it was not operational income and was already taxed in an earlier year. The income was considered extraordinary and not related to the current financial year's costs, thus not suitable for transfer pricing adjustments.

3. Rejection of Segmental Results and Adoption of Entity-Level Operating Margins:
The TPO rejected the segmental results certified by cost auditors and adopted entity-level margins for transfer pricing adjustments. The tribunal found this approach incorrect, directing the TPO to base his analysis on segmental financials and to re-evaluate comparables. The tribunal emphasized the need for segmental analysis due to the distinct business segments of API and PDS.

4. Inclusion of Reimbursement of Expenses in Operating Sales:
The tribunal directed the TPO to examine whether the Rs. 3.05 crores received as reimbursement were indeed reimbursements and not part of the operating sales. If confirmed as reimbursements, they should be excluded from operating profits.

5. Deduction of Disallowed Expenditure in a Sister Concern:
The tribunal rejected the assessee's claim to reduce its adjustment by amounts disallowed in a sister concern, stating that taxability in one entity does not affect the adjustment in another unless specified by the Act.

6. Benefit of the +/- 5% Standard Deduction under Section 92C(2):
The tribunal directed the Assessing Officer to consider the +/- 5% standard deduction as per the Act's provisions if the ALP determined is within the range.

7. Deduction under Section 10B for the Export Oriented Undertaking:
The tribunal upheld the DRP's direction to follow the outcome of the pending High Court decision regarding the eligibility of the unit for section 10B deduction. The matter was considered sub judice and was allowed for statistical purposes.

8. Deduction of Employee Stock Option Scheme (ESOP) Expenses:
The tribunal restored the issue to the Assessing Officer to be examined in light of the Special Bench decision in Biocon Limited, which allowed ESOP expenses as deductible.

9. Apportionment of Common Corporate Overhead Expenses:
The tribunal found the assessee's method of allocating corporate overheads based on cost accounting principles more rational than the Assessing Officer's turnover-based method. The tribunal directed the Assessing Officer to accept the assessee's allocation.

10. Depreciation on Non-Compete Fee:
The tribunal allowed depreciation on the written-down value of non-compete fees paid to Medispan Ltd. but rejected the claim for depreciation on the non-compete fee paid to Concord Biotech Ltd., stating it does not qualify as an intangible asset under section 32(1).

11. Weighted Deduction under Section 35(2AB):
The tribunal directed the Assessing Officer to allow the weighted deduction at 150% of the actual R&D expenditure certified by the prescribed authority, which was Rs. 32,73,07,418/-.

12. Deduction for R&D Expenditure Not Eligible for Weighted Deduction:
The tribunal directed the Assessing Officer to allow the deduction of Rs. 56,35,712/- under section 35(1) for R&D expenditure not eligible for weighted deduction under section 35(2AB).

Conclusion:
The tribunal provided detailed directions on each issue, emphasizing adherence to segmental financials, proper examination of reimbursements, rational allocation of overheads, and compliance with legal precedents for ESOP expenses and non-compete fees. The appeal was partly allowed for statistical purposes.

---